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differentiated: 13 £ MRS5 < 26, 26 £ MRS4 < 62, and
62 £ MRS(0 + 1 + 2 + 3) £91. Each wave, baseline, 1, 3,
and 6 month showed similar trend in cut-offs. CON-
CLUSIONS: The categorization scheme developed can
serve as a crosswalk between measures. However, due to
the ceiling effect of the BI and M-FIM, the crosswalk
could not be completed for all six distinct levels in the
MRS. No apparent variation over time in the categoriza-
tion scheme was observed.
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OBJECTIVES: To evaluate an intervention to reduce
inappropriate use of key antibiotics. METHODS: The
intervention was a policy for appropriate use of Alert
Antibiotics (carbapenems, glycopeptides, amphotericin,
ciproﬂoxacin, linezolid, piperacillin tazobactam and third
generation cephalosporins) implemented through concur-
rent, patient speciﬁc feedback by clinical pharmacists in
a tertiary university hospital. Statistical signiﬁcance and
effect size were calculated by segmented regression analy-
sis of interrupted time series of drug use and cost for two
years before and after the intervention started. RESULTS:
Use of Alert Antibiotics increased before the intervention
started but decreased steadily thereafter. The changes in
slope of the time series were 0.27 Deﬁned Daily
Doses/100bed days per month (95% CI 0.19–0.34 P <
0.0001) and £1908 per month (95% CI £1238–£2578 
P < 0.0001). The cost of development, dissemination and
implementation of the intervention (£20,133) was well
below the most conservative estimate of the reduction in
cost (£133,296), which is the lower 95% CI of effect size
assuming that cost would not have continued to increase
without the intervention. However, if use had continued
to increase, the difference between predicted and actual
cost of Alert Antibiotics was £572,448 (95% CI
£435,696–£709,176 P < 0.0001) over the 24 months after
the intervention started. CONCLUSIONS: Segmented
regression analysis of pharmacy stock data is a simple,
practical and robust method for measuring the impact of
interventions to change prescribing. The Alert Antibiotic
monitoring programme was associated with signiﬁcant
decreases in total use and cost in the two years after the
programme. In our hospital the value of the data far
exceeded the cost of processing and analysis.
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OBJECTIVE: The work-up of patients with faecal incon-
tinence can contain multiple tests, including endoanal
MRI, defecography and anorectal functional testing. In
the search of an optimal diagnostic work-up it is gener-
ally accepted that costs and effectiveness data are
required. However, test differences could also be found in
the amount of patient burden. The aim of this study is to
evaluate the burden of tests used in the evaluation of
patients with faecal incontinence. METHODS: Consent-
ing consecutive patients underwent a standard testing
protocol. Burden of testing was evaluated with a self-
administered questionnaire. The main variables were
anxiety, embarrassment, pain and discomfort, all mea-
sured on a 1 (low) to 5 (high) point-scale. An overall
burden score was calculated by summing the scores of the
four variables. In addition, patients were asked to rank
the three tests from least to most inconvenient and to indi-
cate whether they would advice the tests to friends/rela-
tives. Statistical analysis was performed with Friedman
tests. RESULTS: Data from 93 patients (14 men; mean
age 60 (range 32 to 80)) were analysed. There were
between test differences in terms of total burden, pain
(less for MRI than with anorectal functional testing (p <
0.05)) and discomfort (lower for MRI compared to
defecography (p < 0.05)), as well as embarrassment
(lowest score for MRI and highest for defecography).
Overall, MRI was preferred more often than defecogra-
phy and functional testing, with 71% of the patients
scoring MRI as least inconvenient. Patients would advice
all tests to a friend/relative. CONCLUSION: This study
shows signiﬁcant differences in patient burden for
medical tests to evaluate faecal incontinence, although
this burden seems to be accepted by all participants.
When evaluating medical tests for patients with inconti-
nence, these ﬁndings can complement data on costs and
effectiveness to develop the optimal strategy, minimizing
total patient burden while achieving adequate diagnostic
effectiveness.
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OBJECTIVES: To develop a new method that objectively
evaluates and compares provider efﬁciency in diabetes
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care integrating multiple measures of both resource use
and clinical outcomes. Contemporary performance
assessment technology only evaluates one outcome
measure at a time and does not consider resource use.
METHODS: The basis for comparison is the technical
efﬁciency with which providers transform resources into
outcomes relative to peers. By identifying the highest level
of performance—the efﬁciency frontier—the relative efﬁ-
ciency of each provider under evaluation is quantiﬁed.
Relative efﬁciency is determined among diabetes care
teams at Steno Diabetes Center, Denmark, over a 6-year
period (1995–2000). Applied outcome measures follow
recommendations of the Diabetes Quality Improvement
Project and resources include clinical tests and patient
care time of physicians, nurses and dieticians. Data Envel-
opment Analysis (DEA), a linear programming opti-
mization technique, estimates relative efﬁciency, while
regression analysis (RA) examines the robustness of the
method. Impact of case-mix differences is examined by
subgroup analysis. RESULTS: Over the study period,
DEA identiﬁed a total of four teams on the frontier for
clinical tests and ten teams for patient care time. Below
frontier practice implied a 7% excess use of HbA1c tests,
12% blood pressure tests and 22% lipid measurements
and 6% physician, 5% nurse and 13% dietician care
time. Subgroup estimates implied less variation across
teams and up to 30% reduction in predicted excess use
of resources. When adjusting for clinical outcomes, RA
identiﬁed an excess use of resources among the same
teams operating below frontier in DEA. CONCLU-
SIONS: The method appears robust in identifying per-
formance below frontier set by peers and a useful
diagnostic tool for identifying efﬁciency gaps and setting
targets for performance improvement in diabetes care.
Identiﬁcation of major subgroups in outcomes and
resource use is important for practical implementation of
the method.
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OBJECTIVES: Although breast cancer is highly prevalent
and the third leading cause of mortality for women in
Europe, little is known about treatment patterns for
women with this disease. Intra- or cross-country com-
parisons of treatment patterns are difﬁcult due to the
absence of automated data systems that capture clinical
or health care claims records for representative popula-
tion samples. To overcome this barrier, we designed and
developed a web-based study to determine patterns of
care in advanced stage breast cancer for France, England,
Italy, Spain, and Germany. METHODS: The study
includes three components: 1) survey design and valida-
tion; 2) web-translation of the survey; and 3) identiﬁca-
tion and recruitment of physicians to complete the survey.
Survey Design: Country-speciﬁc and international treat-
ment guidelines were collated into a comprehensive list
of management strategies. The survey is grouped into cat-
egories: Initial evaluation; initial therapy; second and
third-line treatment; monitoring; supportive care. Web
Translation: The web site is designed to elicit speciﬁc
answers rather than open responses. Drop down lists and
check boxes facilitate completion. “Yes” answers to spe-
ciﬁc questions (“Chemotherapy is indicated: Yes/No”)
direct the respondent to more detailed questions on the
topic. Respondents log in with a secure ID/password, and
can enter and exit as many times as is needed. Physician
Recruitment: Physician key opinion leaders (KOLs) with
expertise in breast cancer are recruited from each country
(stratiﬁed by service area) in three separate phases.
RESULTS: In Phase I, KOLs review the “beta” web site,
offering suggestions for improving its accuracy and com-
prehensiveness. In Phase II, a new group of KOLs com-
plete the survey from their home or ofﬁce. In Phase III,
KOLs from Phase I review the summary results and
comment on the ﬁndings. CONCLUSIONS: Although
subject to certain limitations, the web-based survey offers
an efﬁcient strategy to determine practice patterns for
advanced breast cancer.
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OBJECTIVES: Develop a database tool to allow the
administration, acquisition and integration of disparate
medical, pharmacy, enrollment, and provider-speciﬁc
data to measure adherence to a regional antibiotic treat-
ment guideline program. Critical, innovative data man-
agement and patient conﬁdentiality measures were
developed and implemented to build a uniﬁed data set 
of antibiotic prescribing episodes. METHODS: Strong
Square, LLC incorporated the medical, pharmacy and
professional claims from seven participating health plans
in Washington state to create an integrated database of
patient-speciﬁc longitudinal data. This database was used
to measure the impact of previously distributed antibiotic
prescribing guidelines. Recent U.S. Federal regulations
(HIPAA) require non-disclosure of patient-speciﬁc data
and additional reporting limitations imposed by partici-
pating health plans submitting data required that all 
personal-identiﬁers be masked. To address this, Strong
Square, LLC developed a cipher application that masks
all personal identiﬁers without hindering the ability to
